Fig. 6: PDGF-BB activates Akt-dependent NF-κB and ERK-dependent EGR-1 signalling in pericytes.

Pericytes were pre-treated with sunitinib (100 nM), wortmannin (100 nM) or U0126 (10 μM) or vehicle (0.3% DMSO) for 30 min, then treated with vehicle or PDGF-BB (10 ng/mL) for the specified timepoints. Cells were fixed at endpoint and immunostained. Representative images and quantification of a–b pERK, c–d EGR-1 and e–f NF-κB activation following PDGF-BB treatment with or without pathway inhibitors. n = 3, two-way ANOVA. Scale bar = 100 μm. *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle control, #p < 0.05, ##p < 0.01, ###p < 0.001 vs PDGF-BB-treated.